Andrea Ardizzoni

Host-derived immunometabolic biomarkers identify prognostic profiles under immunotherapy in advanced NSCLC: the SARC-LUNG study

Abstract Background Immune checkpoint inhibitors (ICIs) improve outcomes in advanced non-small cell lung cancer (NSCLC), but predictive biomarkers remain limited. Host-derived immunometabolic factors may modulate response to ICIs. Methods In the prospective SARC-LUNG study, 40 pa...